| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 130, 136-146, Copyright © 1988 by American Society for Investigative Pathology
REGULAR ARTICLES |
JH Coggin Jr, SD Rohrer, ED Leinbach, RB Hester, PI Liu and LS Heath
Department of Microbiology and Immunology, University of South Alabama, College of Medicine, Mobile 36688.
X-ray-induced, lymphoblastic, T-cell lymphoma/leukemias from irradiated RF mice were observed to uniformly expressed a 44-kd oncofetal antigen (OFA). The OFA polypeptide was detected by flow cytometry, affinity column SDS-PAGE analysis, and immunoblotting with monoclonal antibody (MAb) 115 prepared against syngeneic mouse fetus. X-ray and ultraviolet (UV) induced murine fibrosarcoma cell lines, used as classic models in radiation biology, were also found to express the OFA, which suggested that the 44-kd OFA was a general transformation marker of tumors. Adult mouse thymocytes and other adult tissues expressed no OFA. The 44-kd polypeptide was located at the surface membrane of the tumors examined. In contrast to other reports, lymphoblastic lymphoma cell lines expressed the OFA as a cross-protective, rather than an individually- specific, tumor-associated transplantation antigen. Pronase treatment removed OFA from the surface of living lymphoma cells, whereas collagenase, neuraminidase, and hyaluronidase did not. The OFA was rapidly reexpressed upon culture of the pronase-treated cells. Taken together, these results suggest that the 44-kd OFA polypeptide described here may provide a useful cell surface marker for future radiation carcinogenesis studies. MAb 115 is a promising reagent for detecting tumor-associated 44-kd OFA, for assessing immunoregulatory perturbations to the OFA caused by radiation damage and for investigating the immunopathology of OFA-associated radiation damage.
This article has been cited by other articles:
![]() |
B. Friedrichs, S. Siegel, M. Kloess, A. Barsoum, J. Coggin Jr., J. Rohrer, I. Jakob, M. Tiemann, K. Heidorn, C. Schulte, et al. Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia J. Immunol., May 1, 2008; 180(9): 6374 - 6384. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Siegel, A. Wagner, B. Friedrichs, A. Wendeler, L. Wendel, D. Kabelitz, J. Steinmann, A. Barsoum, J. Coggin, J. Rohrer, et al. Identification of HLA-A*0201-Presented T Cell Epitopes Derived from the Oncofetal Antigen-Immature Laminin Receptor Protein in Patients with Hematological Malignancies. J. Immunol., June 1, 2006; 176(11): 6935 - 6944. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Siegel, A. Wagner, D. Kabelitz, M. Marget, J. Coggin Jr, A. Barsoum, J. Rohrer, N. Schmitz, and M. Zeis Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies Blood, December 15, 2003; 102(13): 4416 - 4423. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Rohrer, A. L. Barsoum, D. L. Dyess, J. A. Tucker, and J. H. Coggin Jr. Human Breast Carcinoma Patients Develop Clonable Oncofetal Antigen-Specific Effector and Regulatory T Lymphocytes J. Immunol., June 1, 1999; 162(11): 6880 - 6892. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |